Clinical Trials · NCT04235959
A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 24
- Start date
- Oct 2020
- Locations
- 2 sites, China
- Primary endpoint
- Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration.